News Bulletin
Wednesday, October 07, 2026
Evening Edition
Economic Numbers:
|
Time |
Event |
Actual |
Forecast |
Previous |
|
7:00 |
-0.042 |
|
-0.06 |
|
|
7:00 |
204.7 |
|
213.6 |
|
|
7:00 |
145.1 |
|
148.2 |
|
|
7:00 |
515.8 |
|
557.8 |
|
|
7:00 |
0.0749 |
|
0.073 |
|
|
10:30 |
-3.186M |
1.900M |
0.922M |
|
|
10:30 |
0.444M |
|
0.553M |
|
|
10:30 |
-0.053M |
|
-0.468M |
|
|
10:30 |
0.223M |
|
-0.554M |
|
|
10:30 |
0.002 |
|
-0.015 |
|
|
10:30 |
-0.117M |
|
-0.124M |
|
|
10:30 |
0.382M |
-1.700M |
-1.684M |
|
|
10:30 |
-0.042M |
-2.100M |
-2.251M |
|
|
10:30 |
0.287M |
|
-0.156M |
|
|
10:30 |
0.668M |
|
-0.620M |
|
|
11:00 |
0.039 |
0.036 |
0.036 |
|
|
13:00 |
0.053 |
|
0.04834 |
|
|
15:00 |
8.28B |
14.50B |
17.74B |
Indices
|
|
CLOSE |
50 DMA |
200 DMA |
|
DJIA |
51,179.87 |
52,651.50 |
50,324.64 |
|
NASDAQ |
27,538.69 |
26,462.38 |
24,798.44 |
|
S&P 500 |
7,801.77 |
7,680.35 |
7,240.02 |
Earnings Calendar:
(EPS: Earning Per Share / Rev: Revenue / Mkt Cap : market Capital/ BMO :
Before Market Opening /AMC : After Market Close)
|
COMPANY |
EPS Act |
EPS
Fore |
Rev
Act |
Rev
Fore |
Mkt Cap |
Fiscal |
Time |
|
-/2.32 |
-/25B |
$189.49B |
Q3 |
AM |
|||
|
-/3.67 |
-/22.89B |
$122.59B |
Q3 |
AM |
|||
|
-/2.03 |
-/17.27B |
$56.08B |
Q3 |
AM |
Market
News:
Here are some of the biggest premarket US stock movers today:
Lattice
Semiconductor (LSCC) announced a
collaboration with Arm to integrate Lattice FPGAs and AMI firmware with
Arm AGI CPU server platforms, targeting secure control and management for AI
data center infrastructure.
Anthropic (NASDAQ:ANTP) announced the launch of Claude Haiku
5.5 on Wednesday, introducing a substantially faster and cheaper small-format
artificial intelligence model aimed at high-volume enterprise workflows and
subagent task execution. The release reflects an aggressive expansion of the company's
tier-priced model matrix as competitive pressure intensifies across the
generative AI ecosystem.
Valneva SE ADRs (NASDAQ:VALN) fell 6.5% in
after-hours trading Wednesday after the UK revoked the marketing authorization
for its IXCHIQ chikungunya vaccine following a
benefit-risk review.
For internal use only